23
Mar
2023
Welcome to the AI Irruption
Biopharma, like the rest of the world, appears to be on the threshold of profound, technology-induced change. Incredible advances in artificial intelligence, manifested most recently in GPT-4, are here. This technology, Ezra Klein explains in the New York Times, “changes everything.” Bill Gates describes it as “the most important advance in technology since the graphical user interface,” and declares, “the... Read More
22
Mar
2023
Flare Therapeutics Gets $123M to Make Drugs Against Elusive Transcription Factors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
18
Mar
2023
Takeda Oral Tyk2 Inhibitor, Acquired in Nimbus Deal, Raises the Bar on Psoriasis
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Mar
2023
Pfizer Acquires Seagen, Sanofi & Novo Cut Insulin Prices, & Illumina’s Proxy Fight
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
16
Mar
2023
The Last Mile of Hepatitis C Treatment
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
15
Mar
2023
Big Pharma, VCs Bet $105M on Mediar’s Antibodies for Fibrotic Diseases
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
14
Mar
2023
The Future of Neuroscience Drug R&D: Ryan Watts on The Long Run
Today’s guest on The Long Run is Ryan Watts. Ryan is the co-founder and CEO of South San Francisco-based Denali Therapeutics. Denali is one of the prominent development-stage biotech companies working on treatments for neurodegenerative diseases. It has a pipeline with seven drug candidates in clinical development. It’s developing small molecules and large molecules against a range of neurodegenerative diseases... Read More
9
Mar
2023
SVB’s Dark Day, Biogen’s Leadership Change, and a Plan to Crush HepC
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
7
Mar
2023
Third Rock, Arch, J&J Pump $100M into Rapport to Develop Precision Neuro Drugs
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
6
Mar
2023
Remote/Hybrid Work is Here to Stay. Biotech Should Embrace It
There has been much debate about the biotech workplace in the aftermath of pandemic disruptions. Employers and employees are all thinking about how and to what extent companies should enable and support remote-based work. People are discussing the advantages and disadvantages of remote work, especially in terms of the effect on productivity and creativity. This matters in biotech. The goal... Read More
2
Mar
2023
Lilly Cuts Insulin Prices, Reata’s Dramatic FDA Approval, & Seagen M&A Rumors
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
28
Feb
2023
A Life in Biotech & the Cell Therapy Wave: David Hallal on The Long Run
Today’s guest on The Long Run is David Hallal. David is the CEO of Waltham, Mass.-based ElevateBio. ElevateBio describes itself as a technology-driven company for cell therapies. It has pulled together gene editing tools, induced pluripotent stem cells, and various viral vectors necessary to modify cells to fight cancer or treat other diseases. David co-founded ElevateBio in 2017 with Mitchell... Read More
26
Feb
2023
The Success of Your Tech Deployment Depends On A Role You’ve Probably Never Heard Of
The success or failure of many technology platforms — including in particular health tech platforms — rests with a largely obscure role of outsized importance: the “solutions engineer.” The role itself goes by many names. Back when I was at DNAnexus in the mid-2010s, this role was called “Solutions Scientist.” Others call it “Forward-Deployed Engineer” or “Embedded Analyst.” Whatever the... Read More
14
Feb
2023
Engineered B-Cell Therapies for Cancer & Rare Diseases: Joanne Smith-Farrell on The Long Run
Today’s guest on The Long Run is Joanne Smith-Farrell. Joanne is the CEO of Cambridge, Mass.-based Be Biopharma. Many listeners of this show are familiar with the explosion of activity in cell therapy. Engineered T cell therapies have delivered extraordinary results for people with certain types of cancer. The success in these personalized T cell therapies, which get modified outside... Read More
10
Feb
2023
Why Is It So Hard to Get Patients the Medicines They Need?
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
9
Feb
2023
First, We Need to Generate the Right Data. Then AI Will Shine
ChatGPT is a hot topic across many industries. Some say the technology underpinning it – called generative AI – has created an “A.I. arms race.” However, relatively little attention is given to what is needed to fully leverage the promise of generative AI in healthcare, and specifically how it may help accelerate drug discovery and development. That’s a mistake. Recently,... Read More
4
Feb
2023
Grand Défi Ou Goulot D’étranglement Ultime: A French Pharma Tackles Data Science
Most biopharma companies have started down the path of digital transformation – a fundamental overhaul of everything they do for the digital age. It’s not clear yet that anyone has arrived at the desired destination. Even so, there have been some early wins, generally related to operations, as the CEOs of both Novartis and Lilly have described. Arguably, the most... Read More
2
Feb
2023
GSK, Lilly Win FDA Approvals, Magenta For Sale, and a Colossal Series B
Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $199 per year, you reward quality independent biotech reporting, and encourage more. Subscribe Now Sign in to your account.
2
Feb
2023
When Life-Saving Medicines Are Ammunition in a Trade War
In early January, I held a telemedicine visit with a patient who reported a positive at-home COVID test and mild shortness of breath. During the visit, I looked through her health conditions and medications and decided that it was appropriate to prescribe Paxlovid. Later that day, she received the prescription from her local pharmacy, free of charge. Afterwards, I called... Read More
1
Feb
2023
A Biotech Journalism Outlet Built to Last: Rick Berke on The Long Run
Today’s guest on The Long Run is Rick Berke. Rick is the co-founder and executive editor of STAT. Just about everyone who listens to The Long Run probably already reads STAT. If you don’t, you should. It’s become a go-to publication for breaking news, features, and in-depth investigative reporting across the world of biotech and healthcare. John Henry, the billionaire... Read More